Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Adagio Medical Holdings, Inc Common Stock (ADGM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ADGM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -31.41% | Avg. Invested days 5 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 54.65M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 108210 | Beta -0.03 | 52 Weeks Range 0.75 - 9.34 | Updated Date 04/1/2025 |
52 Weeks Range 0.75 - 9.34 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.76 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -33903.85% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 98379330 | Price to Sales(TTM) 205.44 |
Enterprise Value 98379330 | Price to Sales(TTM) 205.44 | ||
Enterprise Value to Revenue 369.85 | Enterprise Value to EBITDA - | Shares Outstanding 13387600 | Shares Floating 702889 |
Shares Outstanding 13387600 | Shares Floating 702889 | ||
Percent Insiders 0.33 | Percent Institutions 27.68 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Adagio Medical Holdings, Inc Common Stock
Company Overview
History and Background
Adagio Medical is a medical technology company focused on developing and commercializing innovative solutions for the treatment of atrial fibrillation (Afib). Founded in 2011, Adagio Medical aims to improve patient outcomes through advanced catheter-based technologies that address the limitations of existing Afib treatment options. The company has evolved from early-stage research to commercializing its iCLAS technology in Europe and seeking regulatory approval in the United States.
Core Business Areas
- Cryoablation: Adagio's core business revolves around cryoablation technologies for the treatment of cardiac arrhythmias, specifically atrial fibrillation (Afib).
- iCLAS Technology: Development, manufacturing, and marketing of its Intelligent Continuous Lesion Ablation System (iCLAS) for creating contiguous transmural lesions in the heart.
Leadership and Structure
Adagio Medical is led by a team of experienced medical device executives and scientists. The organizational structure consists of departments dedicated to research and development, manufacturing, sales and marketing, clinical affairs, and regulatory compliance.
Top Products and Market Share
Key Offerings
- iCLAS Catheter: The iCLAS catheter is Adagio Medical's flagship product, designed for creating continuous, transmural lesions in the heart to treat atrial fibrillation. Revenue and market share data are not publicly available due to the company being private. Competitors include Medtronic, Abbott, Boston Scientific.
Market Dynamics
Industry Overview
The cardiac ablation market is experiencing significant growth, driven by the increasing prevalence of atrial fibrillation and advancements in ablation technologies. The market is highly competitive, with major medical device companies vying for market share.
Positioning
Adagio Medical aims to differentiate itself by offering a cryoablation technology that creates contiguous lesions, which may lead to improved clinical outcomes compared to traditional point-by-point ablation methods. Market share data is not currently publicly available for this specific company.
Total Addressable Market (TAM)
The global cardiac ablation market is estimated to be worth billions of dollars. Adagio Medical is positioned to capture a portion of this TAM with its innovative iCLAS technology.
Upturn SWOT Analysis
Strengths
- Innovative cryoablation technology
- Potential for improved clinical outcomes compared to traditional ablation
- Experienced management team
- Strong intellectual property position
Weaknesses
- Limited commercial presence
- Dependence on a single product
- Relatively small company size compared to competitors
- No current FDA approval
Opportunities
- Expansion into new geographic markets
- Development of new applications for iCLAS technology
- Partnerships with larger medical device companies
- FDA approval in the United States
Threats
- Intense competition from established medical device companies
- Technological advancements by competitors
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- MDT
- ABT
- BSX
Competitive Landscape
Adagio Medical faces significant competition from larger, more established medical device companies. Its competitive advantage lies in its innovative cryoablation technology, which has the potential to offer improved clinical outcomes.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not publicly available due to the company's private status.
Future Projections: Future projections are not publicly available.
Recent Initiatives: Adagio Medical is focused on obtaining regulatory approvals, expanding its sales and marketing efforts in Europe, and conducting clinical trials to support the adoption of its iCLAS technology.
Summary
Adagio Medical is a medical device company with innovative cryoablation technology that creates contiguous transmural lesions for treating atrial fibrillation. Though they have the potential for improved clinical outcomes, they face competition from larger, established companies such as Medtronic, Abbott and Boston Scientific. FDA Approval in the United States and partnerships with larger companies are critical milestones. Being a private company, they lack the resources of their competitors and face reimbursement challenges.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
BSX
Boston Scientific Corp
BSX
Boston Scientific Corp
MDT
Medtronic PLC
MDT
Medtronic PLC
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Analyst estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. Financial metrics are not publicly available for this private company.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adagio Medical Holdings, Inc Common Stock
Exchange NASDAQ | Headquaters Laguna Hills, CA, United States | ||
IPO Launch date 2024-08-01 | CEO & Director Mr. Todd Usen | ||
Sector Healthcare | Industry Medical Devices | Full time employees - | Website https://adagiomedical.com |
Full time employees - | Website https://adagiomedical.com | ||
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.